Description | Malcolm Stevens is distinguished for his elegant design and invention of small nitrogen-based heterocycles for treatment of cancer. He is the inventor of 'temozolomide' which is active against brain tumours and licensed by Cancer Research Technologies to Schering Plough Corporation, with sales of $300 million/annum, rising. Three other compounds discovered in his laboratories, ie N-methylformamide, bropirimine and MZPES, have progressed to clinical trials, and bropirimine is now on the market in Japan as RemisarTM. The antitumoral benzothiazole 'phortress' synthesised in Stevens' laboratory has recently been selected for clinical trials in 2003 by Cancer Research UK and the National Cancer Institute. |